Review article

Malignant Pleural Effusion: A Multidisciplinary Approach

Q1 Ana Pardessus [a,*], Albert Rafecas-Codern [a,b], José M. Porcel [c], Pere Serra-Mitjà [a], Lucía Ferreiro [d], Maribel Botana-Rial [e,f], Cristina Ramos-Hernández [g], José Manuel Brenes [h], Lydia Canales [h], V. Camacho [i], Beatriz Romero-Romero [j], Juan Carlos Trujillo [k], Elisabeth Martinez [k], Enrique Cases [l], Andrés Barba [m], Margarita Majem [m], Ernest Güell [n], Virginia Pajares [a,b]

Q2 [a] Interventional Pulmonology, Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma Barcelona (UAB), Barcelona, Spain
[b] Chronic Respiratory Disease Group (GREC), Institut de Recerca Sant Pau (IR SANT PAU), Spain
[c] Pleural Medicine Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, University of Lleida, Lleida, Spain
[d] Pulmonology Department, University Clinical Hospital of Santiago, Interdisciplinary Research Group in Pulmonology, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
Q3 [e] Broncopleural Unit, Pulmonary Deparment, Hospital Álvaro Cunqueiro, EOXI Vigo, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), Vigo, Spain
[f] CIBER de Enfermedades Respiratorias, Spain
[g] Pulmonary Deparment, Hospital Álvaro Cunqueiro, EOXI Vigo, PneumoVigoI+i Research Group, Sanitary Research Institute Galicia Sur (IISGS), Vigo, Spain
[h] Radiology Department, Hospital Santa Creu i Sant Pau, Universitat Autónoma Barcelona (UAB), Barcelona, Spain
[i] Nuclear Medicine Department, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
[j] Interventional Pulmonology, Hospital Virgen del Rocío, Sevilla, Spain
[k] Department of Thoracic Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
[l] Interventional Pulmonology, Hospital Universitario Politécnico La Fe, Valencia, Spain
[m] Medical Oncology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
[n] Palliative Care Unit, Oncology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma Barcelona (UAB), Barcelona, Spain

A R T I C L E   I N F O

A B S T R A C T

Malignant pleural effusion (MPE) has become an increasingly prevalent complication in oncological patients, negatively impacting their quality of life and casting a shadow over their prognosis. Owing to the pathophysiological mechanisms involved and the heterogeneous nature of the underlying disease, this entity is both a diagnostic and therapeutic challenge. Advances in the understanding of MPE have led to a shift in the treatment paradigm towards a more personalized approach. This article provides a comprehensive review and update on the pathophysiology of MPE and describes the diagnostic tools and the latest advances in the treatment of this complex clinical entity.

Derrame pleural maligno: un enfoque multidisciplinar

R E S U M E N

El derrame pleural maligno (DPM) se ha convertido en una complicación cada vez más prevalente en los pacientes oncológicos, empeorando la calidad de vida y ensombreciendo el pronóstico de los mismos. Debido a los mecanismos fisiopatológicos involucrados y a la naturaleza heterogénea de la enfermedad subyacente, esta entidad representa un desafío diagnóstico y terapéutico. Los avances en la comprensión

* Corresponding author.
  E-mail address: anapardessusotero@gmail.com (A. Pardessus).

del DPM han originado un cambio en el paradigma del tratamiento hacia un enfoque más personalizado. Este artículo proporciona una revisión exhaustiva y una actualización sobre la fisiopatología del DPM, y describe las herramientas diagnósticas y los últimos avances en el tratamiento de esta compleja entidad clínica.

Introduction

Malignant pleural effusion (MPE) is defined as the presence of neoplastic cells in pleural fluid. It can be associated with a primary pleural neoplasm (mesothelioma) or with secondary dissemination from any other location. Approximately 35% of MPE are secondary to lung cancer, which is present at diagnosis in 15% of patients, followed by breast cancer, present in 23% of MPE, and lymphomas in up to 10% of cases.[2] The global incidence of MPE is estimated to be 70 per 100,000 individuals per year.[3] Advances in the treatment of oncological pathology have resulted in increased survival. Management of this entity continues to be a clinical challenge, compromising quality of life. Prognosis depends on several factors such as the type of primary cancer, stage, and performance status. Two prognostic scoring systems have been validated for MPE: the LENT and PROMISE scores.[4,5] Both systems combine clinical and biological variables but may not be valid in light of new targeted therapies for lung cancer and molecular subtypes.

Although diagnostic and therapeutic approaches to MPE have improved significantly in recent years, current treatment remains palliative, aiming to reduce symptoms through a variety of approaches, such as repeated thoracentesis, surgical or medical pleurodesis, and indwelling pleural catheters.

The aim of this review is to provide a comprehensive and updated overview of the pathogenesis, diagnosis, and treatment of MPE to guide clinicians in personalized management and optimize patient care.

Pathogenesis of malignant pleural effusion

The mechanism underlying the ability of the pleura to sustain homeostasis has been studied in depth.[6] The quantity of normal pleural fluid (0.26 mL/kg) depends on the balance of hydrostatic and oncotic pressure from the systemic and pulmonary circulation and the pleural space.[6,7] An effusion manifests when fluid production exceeds the capacity of the lymphatic vessels to resorb fluid, resulting from factors such as elevated production, reduced resorption, or both.[8,9]

MPE is typically defined by the presence of cancerous cells, and with the exception of mesothelioma, its occurrence is predominantly the result of metastases in the pleural space.[10,11] The mechanism of metastasis involves the invasion of the pleural space by tumor cells, mainly through the bloodstream, although direct infiltration or lymphatic spread may also occur. After initially invading the visceral pleura, diffusion to the parietal pleura occurs through tumor seeding along adhesions or by malignant cells floating in the fluid. Tumor cells adhere to the mesothelium, circumvent pleural immune defenses, infiltrate pleural tissue, and gain access to nutrients and growth factors.[12,13] Therefore, the accumulation of fluid in the pleural space results from a combination of fluid extravasation from the hyperpermeable pleura or from tumor growth obstructing lymphatic drainage.[14]

MPE is characterized by a protein-rich fluid that comprises growth factors and cytokines, featuring proinflammatory molecules (IL-2, IL-6, and TNF), angiogenic factors (ANG-1 and ANG-2), and vascular permeability markers (VEGF, MMP, c-c motif, CCL, and OPN), as well as immunosuppressive substances such as IL-10.[15] To initiate these processes, tumor cells activate transcriptional factors (nuclear factor NF-κB), signal transducer, and transcription-3 (STAT-3).[12] Subsequently, the host cell IL-5 facilitates the influx of eosinophils and promotes myeloid suppressor cells in the pleura. In addition, mast cells release molecules (TPSAB1 and IL-1β) that enhance pulmonary vessel permeability.[9,16] This interaction between the tumor and host cells establishes a microenvironment that facilitates tumor growth while inhibiting antitumor immune activity.[14,15] Several recent translational studies have shown that the proliferation of cancer cell cultures is enhanced when cells are seeded in pleural fluid.[17] In terms of genetics, genomic studies indicate that certain gene mutations (EGFR, KRAS, PIK3CA, BRAF, MET, EML4/ALK, and RET) are associated with a high risk of MPE formation. Specifically, KRAS mutations are more prevalent in distant metastases and EGFR mutations in tumors with regional metastatic infiltration.[18]

Diagnosis

Pleural fluid analysis

Thoracentesis is a low-risk procedure performed under ultrasound guidance. It helps to establish a definitive diagnosis of malignancy (diagnostic thoracentesis), relieve dyspnea caused by symptomatic effusion (therapeutic thoracentesis), or both. Pleural fluid samples should be sent for biochemical (5 mL) and cytological (≥50 mL) analyses.[3] Malignant pleural fluids have a bloody appearance in approximately 40% of cases.[19] These fluids are virtually always exudates, but one large series showed that 1.9% of 1527 MPE met Light's criteria for a transudate, most with a justifiable concomitant cause.[20] The predominant cells in the pleural fluid differential white cell count are lymphocytes in about 85% of cases, pleural fluid glucose is ≤60 mg/dL in 9%, pleural fluid pH is below 7.2 in 6%, and adenosine deaminase is ≥35 U/L in 5%.[19]

Cytology of pleural fluid is the most straightforward method to reveal the presence of malignancy. The occurrence of positive results is influenced by factors such as the primary tumor, the quantity of individual specimens examined, and the method of sample processing.[21] In a meta-analysis comprising over 6000 patients, the sensitivity of pleural fluid cytology for MPE was 58%, although the diagnostic yield was particularly low for lung squamous cell carcinoma (24%) and mesothelioma (29%).[22] Maximal sensitivity may be achieved after examining two separate samples using both stained smears (Papanicolaou or Giemsa) and cell block (hematoxylin–eosin) preparations.[23] Cell blocks allow the application of immunocytochemical tests to identify primary tumors invading the pleura and to differentiate between reactive mesothelial cells, mesothelioma, and adenocarcinoma. Thus, there are immunocytochemical markers for reactive mesothelial cells (e.g., desmin), mesothelioma (e.g., loss of BAP1 and/or MTAP, HEG1 clone SKM9-2), and carcinoma (e.g., claudin-4, EpCAM, and TTF-1).[21,24–26] The diagnosis of mesothelioma is particularly challenging, although the combination of immunocytochemical tests (BAP1, MTAP) and fluorescence in situ hybridization (FISH)

A. Pardessus, A. Rafecas-Codern, J.M. Porcel et al.

techniques (e.g., homozygous deletion of CDKN2A) has increased diagnostic sensitivity to 80–90%.[27,28]

Determining classical tumor markers in pleural fluid is indicative of malignancy but is not definitive. One study found that 41% of MPE with a false-negative cytological examination and a positive pleural biopsy had pleural fluid levels of CEA >45 ng/mL or CA15-3 >77 UI/L.[29] Increasingly, pleural fluid (particularly the supernatant) is becoming a recognized source for liquid biopsy that allows the phenotypic characterization of tumors in a minimally invasive manner.[30]

Usefulness of pleural manometry

Pleural manometry refers to the direct measurement of pressure within the pleural space using anything from simple water manometers to electronic or digital devices.[31,32] Potential clinical applications of pleural pressure monitoring include the diagnosis of non-expandable lung, prediction of pleurodesis success, and prevention of complications associated with large-volume thoracentesis.[31]

In non-expandable lungs, there is a greater decrease in pressure when the volume is removed. Pleural elastance, a change in pleural pressure divided by the change in the volume of pleural fluid drained, has shown to accurately differentiate non-expandable lung from normal lung,[33] with a cut-off of 14.5 cmH$_2$O/l as the upper limit of normal.[34] If pleural elastance is elevated ($\geq$18 cmH$_2$O/l), the probability of pleurodesis failure is high.[35,36] Therefore, pleural manometry may be recommended to guide the treatment of patients with MPE.

The use of pleural manometry may reduce the risk of complications associated with negative pressure (pulmonary edema due to re-expansion, chest pain, or exvacuo pneumothorax) during therapeutic thoracentesis; however, there is little evidence to support this approach. Several studies have failed to demonstrate that pleural manometry during large-volume thoracentesis reduces the risk of serious complications, discomfort, or breathlessness.[37–39]

Imaging techniques

Ultrasonography

Thoracic ultrasound (TUS) is a noninvasive tool that is cost-effective, portable, and readily available. It allows real-time image acquisition without radiation exposure.[40,41] TUS is highly sensitive for detecting pleural effusion (PE). It can also identify the presence, localization, and characteristics of PE and allow the visualization of adjacent structures.[42]

TUS plays a crucial role in the diagnosis, management, and monitoring of MPE. It is not only accurate, but also provides guidance for procedures, enabling detailed evaluation of the peripheral pleura in the presence of pleural effusion.[3] TUS can reveal fibrin septa (Fig. 1) or loculations,[43,44] pleural thickness, and pleural metastases.[45] Furthermore, it can identify small PE and locate the best site for pleural catheter placement. It can also be useful for evaluating lung re-expansion.[45] International guidelines recommend ultrasound guidance when performing thoracentesis to reduce the risk of complications,[3,40,45] especially in loculated collections.[44] Regarding pleural thickening or nodularity, ultrasound-guided pleural biopsy increases diagnostic accuracy[3,46,47] and is highly sensitive.[45,46]

TUS has demonstrated reasonable sensitivity and high specificity for distinguishing malignant from benign effusions.[48,49] Certain specific ultrasound characteristics have been associated with malignancy, such as pleural/diaphragmatic nodules, pleural thickening >1 cm, diaphragmatic thickening >7 mm, visceral pleural thickening, liver metastasis, and the absence of lung air bronchogram signs.[48,50] The best predictors of malignancy are


Fig. 1. Septate pleural effusion.

pleural or diaphragmatic nodularity (Fig. 2),[3,40,43,50] but they have not proven useful as ruling-out tests for malignancy.[40] Moreover, the detection of pleural thickness >15 mm in B-mode shows high sensitivity for the diagnosis of malignancy.[3,51]

New modalities such as contrast-enhanced ultrasound (CEUS),[51] M-mode and 2D-shear wave elastography[52] could be helpful for differentiating benign from malignant pleural lesions and assessing lung re-expansion.[44,53,54]

Radiological signs

Chest X-ray. The following chest radiographic signs may indicate MPE[55,56] (Fig. 3):

- *Pleural effusion*: A lateral radiograph can detect up to 50 mL of pleural fluid. The possibility of malignant pleural disease should be considered when the liquid has a loculated morphology, when the distribution is unilateral or asymmetrical, when the amount is massive, or in the event of recurrence after drainage.
- *Pleural thickening*: Focal or diffuse nodular thickening of the pleura. Widening of the mediastinal silhouette can indicate thickening of the mediastinal pleura.
- *Displacement of the mediastinal structures*: A radiological sign that may present alone or in association with those previously described.

CT scan. Contrast-enhanced chest computed tomography (CT) is superior to conventional radiography in detecting pleural effusion and thickening. Furthermore, it enables better assessment of the pulmonary parenchyma and mediastinal structures.

- *Pleural effusion*: It allows further characterization of the liquid. Septations, elevated densitometric values (Hounsfield units),[57,58] and loculations are radiological signs suggestive of pleural malignant disease.
- *Pleural thickening*: Features highly suggestive of malignancy are nodular pleural thickening, pleural irregularity, mediastinal pleural involvement, circumferential pleural thickening, and pleural thickness >10 mm.

Although dual-energy CT is a promising tool for the evaluation of pleural lesions, its role in clinical practice has yet to be determined.[59,60]

FDG PET scan. As most malignant tumors have increased [^{18}F]FDG uptake, [^{18}F]FDG PET/CT can be useful in differentiating between benign and MPE.[61,62] To differentiate benign from malignant lesions, Yang et al.[63] developed and validated a PET-CT score, which

Fig. 2. Pleural and diaphragmatic nodules.

Fig. 3. Pleural mesothelioma. (A) Chest radiograph showing massive left pleural effusion, thickening of the parietal pleura (white arrow) and left mediastinal widening (black arrow). (B) Chest CT shows diffuse pleural thickening involving the mediastinal pleura (black asterisk), and loculated pleural effusion (white asterisks).

showed a sensitivity of 89.7% (95% CI: 75.8–97.1%) and a specificity of 88.6% (73.3–96.8%). They found several patterns in the presentation of [18F]FDG uptake by MPE, including linear, nodular, and encasement (Fig. 4). Most cases of mesothelioma have an encasement pattern, but other malignant tumors such as lung cancer and lymphoma may also present this uptake pattern.[64] One potential application of [18F]FDG PET/CT in the context of MPE is to guide biopsy procedures by identifying the region with the highest accumulation of [18F]FDG.[65] [18F]FDG PET/CT can be used to assess the extent of malignant tumors with pleural involvement and will help monitor the response to therapy.[66] Nevertheless, abnormal pleural FDG uptake is not specific for MPE. Inflammatory and infectious disorders, and pleurodesis may result in elevated [18F]FDG uptake.[65]

Image-guided pleural biopsy

Pleural biopsy (PB) is the gold standard for diagnosing MPE.[67,68] Image-guided biopsies can be performed using CT or TUS, and this method has a high diagnostic yield (70–83%)[69,70] (Fig. 5).

When pleural thickening and/or pleural lesions can be identified and targeted for biopsy, the sensitivity is significantly higher.[71] If pleural thickening is >1 cm, the diagnostic sensitivity of CT-guided PB is comparable to that of thoracoscopy.[72,73] Both modalities show a good diagnostic yield, with TUS (84%) and CT guidance (76–100%) accompanied by low complication rates.[70,73]

Image-guided PB is particularly useful in adhered lungs that render medical thoracoscopy unsuitable, and in well-selected cases, it can provide a high diagnostic yield in the hands of trained clinicians.[74]

TUS also offers some advantages pertaining to patient pathways and waiting times. It usually takes less time than CT-guided PB. Furthermore, it can be conducted by physicians during the initial consultation with the patient, without requiring CT and without subjecting patients to ionizing radiation exposure.

Secondary spread from pleural metastases is more likely to initially be found in the lower thoracic parietal pleura. Ultrasound examination may help to identify a more suitable lower location for sampling. Botana-Rial et al. found that the sensitivity of US-assisted PB biopsies in MPE increased by >17% in subjects with MPE compared to closed PB without the asisitance of TUS.[75]

Fig. 4. [^{18}F]FDG PET/CT with left pleural effusion in the CT study (A and B). The [^{18}F]FDG images (C and D) and the [^{18}F]FDG PET/CT fusion images (E and F) present increased glycolytic metabolism with an encapsulation pattern. Pathological diagnosis: mesothelioma.

Fig. 5. Two type of needle closed pleural biopsy. (A) Abram's needle shown in both retracted and extended positions. (B) Cutting-needle (16G).

Management approach

Indwelling pleural catheters

Indwelling pleural catheters (IPCs) are fenestrated silicone tubes. They are tunneled and fixed subcutaneously using a profibrotic polyester cuff, and have a one-way valve as the external endpiece. The drainage valve of an IPCs is an important component of the catheter that enables intermittent drainage at home via a user-friendly tube.[91] In 1999, Putnam et al. published the first randomized trial comparing pleurodesis to IPC for MPE and found that patients with IPC experienced fewer in-hospital complications and a similar improvement in quality of life compared to patients with pleurodesis; however, they had a lower rate of spontaneous pleurodesis and higher rates of late complications.[92] Currently, this type of drainage is mainly used to manage recurrent symptomatic MPE, aiming to improve quality of life by offering long-term symptom control with the same effectiveness as talc pleurodesis.[45] IPC may alleviate dyspnea in 95% of patients with

MPE.[93] It was initially indicated when the lung did not expand and for patients with symptomatic and loculated fluid accumulation after a failed attempt at pleurodesis.[94] IPC and chemical pleurodesis have demonstrated a similar improvement in symptoms. IPC can be inserted in the outpatient setting and produces spontaneous pleurodesis in 24–58% of patients with MPE. Furthermore, it is associated with fewer requirements for additional pleural interventions.[93,95–98] The IPC drainage schedule is usually determined based on the symptoms. To achieve earlier spontaneous pleurodesis, daily drainage has been compared with drainage every other day, or symptom-guided drainage. Previous studies have shown that early pleurodesis is achieved with daily drainage, but without differences in quality of life, performance status, or patient satisfaction compared with other drainage intervals.[97,99] In addition, in the lung that is not trapped, instillation of talc through the IPC produces spontaneous pleurodesis earlier. Complications of IPC are infrequent, and include catheter malfunction, infection, and symptomatic loculation. Infections such as empyema occur in approximately 5% of cases, and mortality related to such infections

Fig. 6. Indwelling pleural catheter insertion technique.

is less than 1%,[100,101] including patients undergoing oncological treatment in whom the IPC can be placed at any time during oncological treatment without altering the efficacy and safety of IPC.[102] Unless drainage is inadequate, most catheter-related infections can be treated by leaving the IPC in place, supplemented with systemic antibiotic therapy and intrapleural enzyme therapy through the catheter.[103] Another complication is symptomatic loculation, which is treated with intrapleural enzyme therapy.[104] The recently published European and American guidelines state that both IPC and pleurodesis are definitive first-line interventions for symptomatic MPE with expandable lungs, and IPC is also recommended for patients with non-expandable lungs or those with failed pleurodesis[44,105] (Fig. 6).

Pleurodesis

Pleurodesis refers to the process of obliterating the pleural space through the induction of pleural inflammation and fibrosis. This is accomplished through the use of a sclerosant or manual abrasion (mechanical). Mechanical pleurodesis, such as pleural abrasion, may be an option for patients with recurrent MPE. However, this procedure requires a surgical approach (thoracoscopy). Mechanical pleurodesis could be technically difficult if previous attempts at nonsurgical pleurodesis are partially successful or if the effusion is significantly loculated.[83] It can also be combined with chemical pleurodesis; however, it is unclear whether this increases the efficacy of the procedure. The presence of vascularized lesions in the pleura may increase the risk of bleeding after abrasion. In contrast, in addition to thoracoscopy, chemical pleurodesis can be performed through an IPC or chest tube. Numerous agents have been used for chemical pleurodesis (tetracycline derivatives, silver nitrate, iodopovidone, bleomycin), with talc currently being the agent of choice.[46] The most frequently described complications are chest pain, dyspnea, and fever. To minimize the risk of these complications, talc must be free of contaminants and have a particle size greater than 15 μm.[76] The average administered dose of talc is 4 g.

Fig. 7. Management approach in MPE. IPC, indwelling pleural catheter; MPE, malignant pleural effusion; PE, pleural effusion. *Pleural manometry can be useful in the diagnosis of trapped lung. **It is enough that one of the two answers is negative.

Administration can be either sprayed through a thoracoscope (talc poudrage) or suspended in saline via a chest drain (talc slurry). There are no differences between the two forms of administration, and the complication rate and improvement in symptoms are also similar.[77,78] In general, the success of pleurodesis in terms of reducing the recurrence of pleural effusion 30 days after pleurodesis ranges from 60 to 90%,[79–81] whereas the relapse rate in long-term survivors is 50% at six months of pleurodesis.[81,82] A crucial point to bear in mind is that to ensure optimal pleurodesis, the pleural space must be as dry as possible prior to the application of a sclerosant agent.

Pleurodesis is typically recommended for symptomatic patients with a life expectancy of more than one month, provided they have shown clinical improvement and pulmonary re-expansion after a previous therapeutic thoracentesis (Fig. 7).

Other surgical approaches

Shunt

Pleuroperitoneal shunting is rarely used in patients with refractory MPE. It usually requires thoracoscopy and general anesthesia; however, shunts may also be placed using interventional radiological techniques.[84–86]

Pleurectomy

Total pleurectomy with decortication is a highly invasive procedure that requires thoracotomy in most cases. It is technically challenging, with significant morbidity and mortality, and a long recovery time. Additionally, there is a paucity of evidence to support its use. It is indicated in selected cases that allow for good surgical conditions and long expected survival. Partial pleurectomy/decortication can be performed by thoracoscopy. Despite its greater technical difficulty, this approach leads to quicker recovery and less pain than thoracotomy.[87–90]

Pharmacologic interventions

Update in oncological treatment

Adenocarcinoma is the most frequent subtype of lung cancer associated with MPE. Around 50% of the Caucasian population and up to 70% of the Asian population present some driver molecular alterations that could potentially benefit from targeted therapies with high, rapid, and deep responses.[106,107] Approximately 65% of patients with MPE with oncogenic driver alterations present with an EGFR mutation.[108] In these patients, treatment with osimertinib results in an objective response rate (ORR) of 80%, with a time to response <6 weeks in 69% of patients and a median duration of response (DoR) of 17.2 months.[109] A retrospective series of patients with EGFR mutations who received first-line osimertinib showed a lower ORR in patients with MPE than in those without MPE (58% vs. 71%), although this difference was not statistically significant ($p = 0.443$). Additionally, there were no differences in progression-free survival (PFS) (19.8 months in both groups, $p = 0.693$).[110] Beyond the EGFR mutation, there are no large series on the specific response to MPE with other oncogenic driver alterations such as MET exon 14 skipping and BRAF mutation or ALK, RET, or NTRK fusions, although treatment with tyrosine kinase inhibitors (TKI) offers ORRs of 55 and −85%.[107]

Oncogenic driver alterations are not exclusive to non-small cell lung cancer, as approximately 15% of breast cancer patients present Her2 overexpression or amplification, and treatment ORRs with dual anti-Her2 blockade plus chemotherapy reach 80% with a median DoR of 20.2 months.[111] Another example is melanoma, in which more than 50% of patients present with a BRAF V600 muta-

tion, and treatment with BRAF/MEK inhibitors results in ORRs of 63%.[112]

Regarding chemotherapy (ChT), patients with highly sensitive tumors, such as germ cell tumors and lymphomas, reach a high cure rate despite the presence of MPE. In other tumors, such as small cell lung carcinoma or ovarian carcinoma, despite not having radical intention, ChT achieves ORRs of up to 60% and 75%, respectively.[113,114]

In recent years, immune checkpoint inhibitors (ICI) have become a part of the standard oncologic treatment, either as monotherapy or in combination. The combination of two ICIs achieved 60% ORR in melanoma,[115] the combination of ICI plus anti-vascular endothelial growth factor (VEGF) achieved 56% ORR in renal carcinoma,[116] and the combination of ICI with an antibody–drug conjugate achieved 68% ORR in urothelial carcinoma.[117]

In selected patients in whom a rapid and deep response is expected from oncological treatment, close monitoring of pleural effusion in the first weeks of initiating systemic therapy could help in decision-making concerning pleural management (IPC or pleurodesis) to prevent recurrent thoracentesis.

Palliative care

Dyspnea, pain, cough, and anxiety are the physical and emotional symptoms most frequently associated with MPE.[13,118] Pharmacological treatment, which typically includes the use of opioids, plays a crucial role in effectively alleviating these symptoms and improving the quality of life.[119–127]

Although morphine is the most well-studied opioid, some publications support a similar effectiveness for opioids such as oxycodone, fentanyl, or methadone.[128–130]

The use of benzodiazepines combined with opioids may help improve dyspnea. Benzodiazepines should be considered for patients with accompanying anxiety.[131,132]

If major opioids are not used, cough can be treated[133,134] specifically with minor opioids (codeine, dihydrocodeine). The use of levodropropizine or sodium cromoglycate is also effective.

To ensure optimal symptom control and quality of life, regular assessment and monitoring of the patient's response to treatment are essential.[120,123,126,127]

For better scientific evidence, research with larger numbers of patients, using standardized protocols and quality of life measures, would be necessary.[126,131,134]

Conclusions

MPE is a complex condition that requires a comprehensive approach to establish an accurate diagnosis, optimize oncological treatment, and improve patient quality of life. Management of MPE is challenging and mainly focuses on symptom relief. It involves early assessment of definitive pleural techniques, such as pleurodesis and tunneled pleural catheter insertion, to achieve initial symptom control. It is crucial to conduct follow-ups in multidisciplinary units to monitor patients, assess treatment responses, manage disease progression, and adjust management as needed. Further research is needed to evaluate these controversies and to establish the most beneficial treatment modality.

Funding

Authors' contributions

Conceptualization and supervision: Ana Pardessus, Virginia Pajares.

Writing – original draft: Ana Pardessus, Albert Rafecas-Codern, José M. Porcel, Pere Serra-Mitjà, Lucía Ferreiro, Maribel Botana-Rial, Cristina Ramos-Hernández, José Manuel Brenes, Lydia Canales, V. Camacho, Beatriz Romero-Romero, Juan Carlos Trujillo, Elisabeth Martinez, Enrique Cases, Andrés Barba, Margarita Majem, Ernest Güell, Virginia Pajares.

All authors reviewed and approved the final version of the manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

Uncited reference   Q5

1.

References

1. Gompelmann D, Eberhardt R, Herth FJ. Advanced malignant lung disease: what the specialist can offer. Respiration. 2011;82:111–23, http://dx.doi.org/10.1159/000329703.
2. Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. Executive summary: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143 Suppl.:7S–37S, http://dx.doi.org/10.1378/chest.12-2377.
3. Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, et al. British Thoracic Society Guideline for pleural disease. Thorax. 2023;78 Suppl. 3:s1–42, http://dx.doi.org/10.1136/thorax-2022-219784.
4. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69:1098–104, http://dx.doi.org/10.1136/thoraxjnl-2014-205285.
5. Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol. 2018;19:930–9, http://dx.doi.org/10.1016/S1470-2045(18)30294-8.
6. Wang NS. Anatomy of the pleura. Clin Chest Med. 1998;19:229–40, http://dx.doi.org/10.1016/s0272-5231(05)70074-5.
7. Agostoni E. Mechanics of the pleural space. Physiol Rev. 1972;52:57–128, http://dx.doi.org/10.1152/physrev.1972.52.1.57.
8. Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378:740–51, http://dx.doi.org/10.1056/NEJMra1403503.
9. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor–host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–92, http://dx.doi.org/10.1164/rccm.201203-0465PP.
10. Herrera Lara S, Fernández-Fabrellas E, Juan Samper G, Marco Buades J, Andreu Lapiedra R, Pinilla Moreno A, et al. Predicting malignant and paramalignant pleural effusions by combining clinical, radiological and pleural fluid analytical parameters. Lung. 2017;195:653–60, http://dx.doi.org/10.1007/s00408-017-0032-3.
11. Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management: a review. Medicina (Kaunas). 2019;55:490, http://dx.doi.org/10.3390/medicina55080490.
12. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25:189–98, http://dx.doi.org/10.1183/16000617.0019-2016.
13. Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, et al. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res. 2024;25:47, http://dx.doi.org/10.1186/s12931-024-02684-7.
14. Yalcin NG, Choong CK, Eizenberg N. Anatomy and pathophysiology of the pleura and pleural space. Thorac Surg Clin. 2013;23:1–10, http://dx.doi.org/10.1016/j.thorsurg.2012.10.008, v.
15. Chen YM, Yang WK, Whang-Peng J, Kuo BI, Perng RP. Elevation of interleukin-10 levels in malignant pleural effusion. Chest. 1996;110:433–6, http://dx.doi.org/10.1378/chest.110.2.433.
16. Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125:2317–34, http://dx.doi.org/10.1172/JCI79840.
17. Asciak R, Kanellakis NI, Yao X, Abd Hamid M, Mercer RM, Hassan M, et al. Pleural fluid has pro-growth biological properties which enable cancer cell proliferation. Front Oncol. 2021;11:658395, http://dx.doi.org/10.3389/fonc.2021.658395.

18. Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017;8:15205, http://dx.doi.org/10.1038/ncomms15205.

19. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2011;16:44–52, http://dx.doi.org/10.1111/j.1440-1843.2010.01794.x.

20. Porcel JM, Sancho-Marquina P, Bielsa S. Malignant pleural effusions with transudative characteristics. Gazz Med Ital – Arch Sci Med. 2022;181:482–3, http://dx.doi.org/10.23736/S0393-3660.22.04760-X.

21. Porcel JM. Diagnosis and characterization of malignant effusions through pleural fluid cytological examination. Curr Opin Pulm Med. 2019;25:362–8, http://dx.doi.org/10.1097/MCP.0000000000000593.

22. Kassirian S, Hinton SN, Cuninghame S, Chaudhary R, Iansavitchene A, Amjadi K, et al. Diagnostic sensitivity of pleural fluid cytology in malignant pleural effusions: systematic review and meta-analysis. Thorax. 2023;78:32–40, http://dx.doi.org/10.1136/thoraxjnl-2021-217959.

23. Porcel JM, Quirós M, Gatius S, Bielsa S. Examination of cytological smears and cell blocks of pleural fluid: complementary diagnostic value for malignant effusions. Rev Clin Esp (Barc). 2017;217:144–8, http://dx.doi.org/10.1016/j.rce.2016.11.004.

24. Porcel JM, Palma R, Bielsa S, Esquerda A, Gatius S, Matias-Guiu X, et al. TTF-1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions. Respirology. 2015;20:831–3, http://dx.doi.org/10.1111/resp.12543.

25. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis. 2018;12, http://dx.doi.org/10.1177/1753466618808660, 1753466618808660.

26. Porcel JM, Esquerda A, Bielsa S, Novell A, Sorolla MA, Gatius S, et al. Epithelial cell adhesion molecule (EpCAM) from pleural fluid cell lysates is a highly accurate diagnostic biomarker of adenocarcinomatous effusions. Respirology. 2019;24:799–804, http://dx.doi.org/10.1111/resp.13539.

27. Porcel JM. Pleural mesothelioma. Med Clin (Barc). 2022;159:240–7, http://dx.doi.org/10.1016/j.medcli.2022.03.007.

28. Miller LJ, Holmes IM, Lew M. An updated contextual approach to mesothelial proliferations in pleural effusion cytology leveraging morphology, ancillary studies, and novel biomarkers. Arch Pathol Lab Med. 2023, http://dx.doi.org/10.5858/arpa.2023-0049-RA.

29. Porcel JM, Civit C, Esquerda A, Salud A, Bielsa S. Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: a single-center experience. Arch Bronconeumol. 2017;53:427–31, http://dx.doi.org/10.1016/j.arbres.2016.12.013.

30. Sorolla MA, Sorolla A, Parisi E, Salud A, Porcel JM. Diving into the pleural fluid: liquid biopsy for metastatic malignant pleural effusions. Cancers (Basel). 2021;13:2798, http://dx.doi.org/10.3390/cancers13112798.

31. Hu K, Chopra A, Huggins JT, Nanchal R. Pleural manometry: techniques, applications, and pitfalls. J Thorac Dis. 2020;12:2759–70, http://dx.doi.org/10.21037/jtd.2020.04.04.

32. Lee HJ, Yarmus L, Kidd D, Amador RO, Akulian J, Gilbert C, et al. Comparison of pleural pressure measuring instruments. Chest. 2014;146:1007–12, http://dx.doi.org/10.1378/chest.13-3004.

33. Light RW, Jenkinson SG, Minh VD, George RB. Observations on pleural fluid pressures as fluid is withdrawn during thoracentesis. Am Rev Respir Dis. 1980;121:799–804, http://dx.doi.org/10.1164/arrd.1980.121.5.799.

34. Heidecker Jay T, Huggins John MDT, Doelken Peter MD, Ravenel James MD, Sahn Steven MDAMD. Pre- and postthoracentesis chest radiographic findings do not predict abnormal pleural elastance. Poster presentations. Chest. 2006;130 Suppl. 244S, http://dx.doi.org/10.1378/chest.130.4.1173.

35. Lan RS, Lo SK, Chuang ML, Yang CT, Tsao TC, Lee CH. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med. 1997;126:768–74, http://dx.doi.org/10.7326/0003-4819-126-10-199705150-00003.

36. Ferreiro L, San José E, Gude F, Valdés L. Pleural fluid analysis and pleural elastance as predictors of response to pleurodesis in patients with malignant pleural effusion. Arch Bronconeumol. 2018;54:163–5, http://dx.doi.org/10.1016/j.arbres.2017.07.020.

37. Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of reexpansion pulmonary edema. Ann Thorac Surg. 2007;84:1656–61, http://dx.doi.org/10.1016/j.athoracsur.2007.06.038.

38. Pannu J, DePew ZS, Mullon JJ, Daniels CE, Hagen CE, Maldonado F. Impact of pleural manometry on the development of chest discomfort during thoracentesis: a symptom-based study. J Bronchology Interv Pulmonol. 2014;21:306–13, http://dx.doi.org/10.1097/LBR.0000000000000095.

39. Lentz RJ, Lerner AD, Pannu JK, Merrick CM, Roller L, Walston C, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med. 2019;7:447–55, http://dx.doi.org/10.1016/S2213-2600(18)30421-1.

40. Shiroshita A, Nozaki S, Tanaka Y, Luo Y, Kataoka Y. Thoracic ultrasound for malignant pleural effusion: a systematic review and meta-analysis. ERJ Open Res. 2020;6, http://dx.doi.org/10.1183/23120541.00464-2020, 00464-2020.

41. Koegelenberg CF, von Groote-Bidlingmaier F, Bolliger CT. Transthoracic ultrasonography for the respiratory physician. Respiration. 2012;84:337–50, http://dx.doi.org/10.1159/000339997.

42. Yousefifard M, Baikpour M, Ghelichkhani P, Asady H, Shahsavari Nia K, Moghadas Jafari A, et al. Screening performance characteristic of ultrasonography and radiography in detection of pleural effusion: a meta-analysis. Emerg (Tehran). 2016;4:1–10.

43. Romero Romero B, Vollmer Torrubiano I, Martín Juan J, Heili Frades S, Pérez Pallares J, Pajares Ruiz V, et al. Ultrasound in the study of thoracic diseases: innovative aspects. Arch Bronconeumol. 2024;60:33–43, http://dx.doi.org/10.1016/j.arbres.2023.10.009.

44. Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019;55:116–32, http://dx.doi.org/10.1093/ejcts/ezy258.

45. Desai NR, Lee HJ. Diagnosis and management of malignant pleural effusions: state of the art in 2017. J Thorac Dis. 2017;9 Suppl. 10:S1111–22, http://dx.doi.org/10.21037/jtd.2017.07.79.

46. Botana Rial M, Pérez Pallarés J, Cases Viedma E, López González FJ, Porcel JM, Rodríguez M, et al. Diagnosis and treatment of pleural effusion recommendations of the Spanish Society of Pulmonology and Thoracic Surgery. Update 2022. Arch Bronconeumol. 2023;59:27–35, http://dx.doi.org/10.1016/j.arbres.2022.09.017.

47. Lin Z, Wu D, Wang J, Wang C, Huang M. Diagnostic value of ultrasound-guided needle biopsy in undiagnosed pleural effusions: a systematic review and meta-analysis. Medicine (Baltimore). 2020;99:e21076, http://dx.doi.org/10.1097/MD.0000000000021076.

48. Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax. 2009;64:139–43, http://dx.doi.org/10.1136/thx.2008.100545.

49. Zhang Q, Deng MM, Li XL, Lu Y, Hou G. Thoracic ultrasound-guided real-time pleural biopsy in the diagnosis of pleural diseases: a systematic review and meta-analysis. Expert Rev Respir Med. 2023;17:805–13, http://dx.doi.org/10.1080/17476348.2023.2266377.

50. Bugalho A, Ferreira D, Dias SS, Schuhmann M, Branco JC, Marques Gomes MJ, et al. The diagnostic value of transthoracic ultrasonographic features in predicting malignancy in undiagnosed pleural effusions: a prospective observational study. Respiration. 2014;87:270–8, http://dx.doi.org/10.1159/000357266.

51. Findeisen H, Görg C, Hartbrich R, Dietrich CF, Görg K, Trenker C, et al. Contrast-enhanced ultrasound is helpful for differentiating benign from malignant parietal pleural lesions. J Clin Ultrasound. 2022;50:90–8, http://dx.doi.org/10.1002/jcu.23088.

52. Jiang B, Li XL, Yin Y, Zhang Q, Zang T, Song WS, et al. Ultrasound elastography: a novel tool for the differential diagnosis of pleural effusion. Eur Respir J. 2019;54:1802018, http://dx.doi.org/10.1183/13993003.02018-2018.

53. Petersen JK, Fjaellegaard K, Rasmussen DB, Alstrup G, Høegholm A, Sidhu JS, et al. Ultrasound in the diagnosis of non-expandable lung: a prospective observational study of M-mode, B-mode, and 2D-shear wave elastography. Diagnostics (Basel). 2024;14:204, http://dx.doi.org/10.3390/diagnostics14020204.

54. Jacobs B, Sheikh G, Youness HA, Keddissi JI, Abdo T. Diagnosis and management of malignant pleural effusion: a decade in review. Diagnostics (Basel). 2022;12:1016, http://dx.doi.org/10.3390/diagnostics12041016.

55. Armstrong P, Wilson A, Dee P, Hansell D. Imaging of diseases of the chest, 3rd edn. Eur J Radiol. 2001;40:154, http://dx.doi.org/10.1016/S0720-048X(01)00333-3.

56. Kuhlman JE, Singha NK. Complex disease of the pleural space: radiographic and CT evaluation. Radiographics. 1997;17:63–79, http://dx.doi.org/10.1148/radiographics.17.1.9017800.

57. Abramowitz Y, Simanovsky N, Goldstein MS, Hiller N. Pleural effusion: characterization with CT attenuation values and CT appearance. AJR Am J Roentgenol. 2009;192:618–23, http://dx.doi.org/10.2214/AJR.08.1286.

58. Çullu N, Kalemci S, Karakaş Ö, Eser I, Yalçin F, Boyacı FN, et al. Efficacy of CT in diagnosis of transudates and exudates in patients with pleural effusion. Diagn Interv Radiol. 2014;20:116–20, http://dx.doi.org/10.5152/dir.2013.13066.

59. Lennartz S, Le Blanc M, Zopfs D, Große Hokamp N, Abdullayev N, Laukamp KR, et al. Dual-energy CT-derived iodine maps: use in assessing pleural carcinomatosis. Radiology. 2019;290:796–804, http://dx.doi.org/10.1148/radiol.2018181567.

60. Odisio EG, Truong MT, Duran C, de Groot PM, Godoy MC. Role of dual-energy computed tomography in thoracic oncology. Radiol Clin North Am. 2018;56:535–48, http://dx.doi.org/10.1016/j.rcl.2018.03.011.

61. Porcel JM, Hernández P, Martínez-Alonso M, Bielsa S, Salud A. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2015;147:502–12, http://dx.doi.org/10.1378/chest.14-0820.

62. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, et al. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg. 2009;57:217–21, http://dx.doi.org/10.1055/s-2008-1039314.

63. Yang MF, Tong ZH, Wang Z, Zhang YY, Xu LL, Wang XJ, et al. Development and validation of the PET-CT score for diagnosis of malignant pleural effusion. Eur J Nucl Med Mol Imaging. 2019;46:1457–67, http://dx.doi.org/10.1007/s00259-019-04287-7.

64. Cohen SE, Betancourt J, Soo Hoo GW. Pleural uptake patterns in F18 fluorodeoxyglucose-positron emission tomography (FDG-PET) scans improve the identification of malignant pleural effusions. J Clin Med. 2023;12:6977, http://dx.doi.org/10.3390/jcm12226977.

65. Long NM, Smith CS. Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging. Insights Imaging. 2011;2:679–98, http://dx.doi.org/10.1007/s13244-010-0062-3.

66. Meignan M, Paone G. 18-Fluoro-deoxy-glucose (FDG) positron emission tomography (PET) for the evaluation of malignant pleural disease. Rev Pneumol Clin. 2006;62:128–34, http://dx.doi.org/10.1016/S0761-8417(06)75427-X.

67. Chang CH, Ost DE. Malignant pleural disease: a pragmatic guide to diagnosis. Curr Opin Pulm Med. 2022;28:282–7, http://dx.doi.org/10.1097/MCP.0000000000000877.

68. Kapp CM, Lee HJ. Malignant pleural effusions. Clin Chest Med. 2021;42:687–96, http://dx.doi.org/10.1016/j.ccm.2021.08.004.

69. Thomas R, Roy B, Maldonado F, Lee YCG. Management of malignant pleural effusions – what is new. Semin Respir Crit Care Med. 2019;40:323–39, http://dx.doi.org/10.1055/s-0039-1698285.

70. Mei F, Bonifazi M, Rota M, Cirilli L, Grilli M, Duranti C, et al. Diagnostic yield and safety of image-guided pleural biopsy: a systematic review and meta-analysis. Respiration. 2021;100:77–87, http://dx.doi.org/10.1159/000511626.

71. Durgeshwar G, Mohapatra PR, Bal SK, Mishra P, Bhuniya S, Panigrahi MK, et al. Comparison of diagnostic yield and complications in ultrasound-guided closed pleural biopsy versus thoracoscopic pleural biopsy in undiagnosed exudative pleural effusion. Cureus. 2022;14:e23809, http://dx.doi.org/10.7759/cureus.23809.

72. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010;137:1362–8, http://dx.doi.org/10.1378/chest.09-0884.

73. Wei Y, Shen K, Lv T, Liu H, Wang Z, Wu J, et al. Comparison between closed pleural biopsy and medical thoracoscopy for the diagnosis of undiagnosed exudative pleural effusions: a systematic review and meta-analysis. Transl Lung Cancer Res. 2020;9:446–58, http://dx.doi.org/10.21037/tlcr.2020.03.28.

74. Hallifax RJ, Corcoran JP, Ahmed A, Nagendran M, Rostom H, Hassan N, et al. Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest. 2014;146:1001–6, http://dx.doi.org/10.1378/chest.14-0299.

75. Botana-Rial M, Leiro-Fernández V, Represas-Represas C, González-Piñeiro A, Tilve-Gómez A, Fernández-Villar A. Thoracic ultrasound-assisted selection for pleural biopsy with Abrams needle. Respir Care. 2013;58:1949–54, http://dx.doi.org/10.4187/respcare.02378.

76. Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med. 2004;170:377–82, http://dx.doi.org/10.1164/rccm.200311-1579OC.

77. Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020;4:CD010529, http://dx.doi.org/10.1002/14651858.CD010529.pub3.

78. Bhatnagar R, Kahan BC, Morley AJ, Keenan EK, Miller RF, Rahman NM, et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. Trials. 2015;16:48, http://dx.doi.org/10.1186/s13063-015-0563-y.

79. Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2020;4:CD010529, http://dx.doi.org/10.1002/14651858.CD010529.pub3.

80. Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T, et al. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg. 2007;83:1940–5, http://dx.doi.org/10.1016/j.athoracsur.2007.02.061.

81. Fortin M, Tremblay A. Pleural controversies: indwelling pleural catheter vs. pleurodesis for malignant pleural effusion. J Thorac Dis. 2015;7:1052–7, http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.51.

82. Dresler CM, Olak J, Herndon JE 2nd, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–15, http://dx.doi.org/10.1378/chest.127.3.909.

83. Hojski A, Leitgeb M, Crnjac A. Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study. Radiol Oncol. 2015;49:386–94, http://dx.doi.org/10.1515/raon-2015-0002.

84. Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions. Eur J Cardiothorac Surg. 2000;18:143–6, http://dx.doi.org/10.1016/s1010-7940(00)00422-x.

85. Shimmyo T, Morita K, Mineshita M, Tagaya R, Ando K, Mochizuki A, et al. Pleuroperitoneal shunt for chylothorax and chylopericardium in lung cancer: a case report. Ann Thorac Cardiovasc Surg. 2011;17:63–6, http://dx.doi.org/10.5761/atcs.cr.09.01482.

86. Khiatani V, Isaacson A, Yu H, Stavas J. Interventional radiologic placement of Denver pleuroperitoneal shunt for refractory chylothorax. J Vasc Interv Radiol. 2013;24:1073–4, http://dx.doi.org/10.1016/j.jvir.2013.03.012.

87. Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2008;33:83–8, http://dx.doi.org/10.1016/j.ejcts.2007.09.039.

88. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6, http://dx.doi.org/10.1016/j.jtcvs.2007.10.054, 626.e1–3.

89. Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (Meso-VATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118–27, http://dx.doi.org/10.1016/S0140-6736(14)60418-9.

90. Ohta Y, Shimizu Y, Matsumoto I, Tamura M, Oda M, Watanabe G. Retrospective review of lung cancer patients with pleural dissemination after limited operations combined with parietal pleurectomy. J Surg Oncol. 2005;91:237–42, http://dx.doi.org/10.1002/jso.20333.

91. Michaud G, Barclay P, Tremblay A. Tunneled pleural catheters for palliation of malignant pleural effusions. J Bronchol. 2005;12:245–8, http://dx.doi.org/10.1097/01.lab.0000185782.99433.02.

92. Putnam JB Jr, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86:1992–9.

93. Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26:70–6, http://dx.doi.org/10.1007/s11606-010-1472-0.

94. Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, et al. Summary for clinicians: clinical practice guideline for management of malignant pleural effusions. Ann Am Thorac Soc. 2019;16:17–21, http://dx.doi.org/10.1513/AnnalsATS.201809-620CME.

95. Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters. Respiration. 2004;71:559–66, http://dx.doi.org/10.1159/000081755.

96. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8, http://dx.doi.org/10.1378/chest.129.2.362.

97. Wahidi MM, Reddy C, Yarmus L, Feller-Kopman D, Musani A, Shepherd RW, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP Trial. Am J Respir Crit Care Med. 2017;195:1050–7, http://dx.doi.org/10.1164/rccm.201607-1404OC.

98. Chaddha U, Agrawal A, Bhavani SV, Sivertsen K, Donington DJ, Ferguson MK, et al. Thoracic ultrasound as a predictor of pleurodesis success at the time of indwelling pleural catheter removal. Respirology. 2021;26:249–54, http://dx.doi.org/10.1111/resp.13937.

99. Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6:671–80, http://dx.doi.org/10.1016/S2213-2600(18)30288-1.

100. Fysh ETH, Tremblay A, Feller-Kopman D, Mishra EK, Slade M, Garske L, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest. 2013;144:1597–602, http://dx.doi.org/10.1378/chest.12-3103.

101. Gilbert CR, Lee HJ, Skalski JH, Maldonado F, Wahidi M, Choi PJ, et al. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study. Chest. 2015;148:752–8, http://dx.doi.org/10.1378/chest.14-3119.

102. Porcel JM, Cordovilla R, Tazi-Mezalek R, Barrios-Barreto D, Pérez-Pallarés J, Novais E, et al. Efficacy and safety of indwelling catheter for malignant pleural effusions related to timing of cancer therapy: a systematic review. Arch Bronconeumol. 2023;59:566–74, http://dx.doi.org/10.1016/j.arbres.2023.06.007.

103. Fitzgerald DB, Muruganandan S, Tsim S, Ip H, Asciak R, Walker S, et al. Intrapleural fibrinolytics and deoxyribonuclease for treatment of indwelling pleural catheter-related pleural infection: a multi-center observational study. Respiration. 2021;100:452–60, http://dx.doi.org/10.1159/000514643.

104. Sidhu C, Davies HE, Muruganandan S, Lui MMS, Lau EPM, Lee YCG. Indwelling pleural catheter: management of complications. Semin Respir Crit Care Med. 2023;44:454–61, http://dx.doi.org/10.1055/s-0043-1769093.

105. Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, et al. Management of malignant pleural effusions an official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839–49, http://dx.doi.org/10.1164/rccm.201807-1415ST.

106. Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25, http://dx.doi.org/10.1200/JCO.21.01626.

107. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358–76, http://dx.doi.org/10.1016/j.annonc.2022.12.013.

108. Jin S, Zhou C, Hou X, Fan Z, Zhao J, Ai X, et al. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer. Transl Lung Cancer Res. 2020;9:1507–15, http://dx.doi.org/10.21037/tlcr-20-882.

109. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25, http://dx.doi.org/10.1056/NEJMoa1713137.

110. Nokihara H, Ogino H, Mitsuhashi A, Kondo K, Ogawa E, Ozaki R, et al. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion. BMC Cancer. 2022;22:597, http://dx.doi.org/10.1186/s12885-022-09701-2.

111. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–34, http://dx.doi.org/10.1056/NEJMoa1413513.

112. Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib

in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603–15, http://dx.doi.org/10.1016/S1470-2045(18)30142-6.

113. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9, http://dx.doi.org/10.1056/NEJMoa1809064.

114. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, et al. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374:738–48, http://dx.doi.org/10.1056/NEJMoa1505067.

115. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56, http://dx.doi.org/10.1056/NEJMoa1709684.

116. Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829–41, http://dx.doi.org/10.1056/NEJMoa2026982.

117. Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390:875–88, http://dx.doi.org/10.1056/NEJMoa2312117.

118. Arora RD, Boster J. Malignant pleural effusion. Treasure Island (FL): StatPearls Publishing; 2024.

119. Feliciano JL, Waldfogel JM, Sharma R, Zhang A, Gupta A, Sedhom R, et al. Pharmacologic interventions for breathlessness in patients with advanced cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2037632, http://dx.doi.org/10.1001/jamanetworkopen.2020.37632.

120. Yamaguchi T, Matsunuma R, Matsuda Y, Tasaki J, Ikari T, Miwa S, et al. Systemic opioids for dyspnea in cancer patients: a real-world observational study. J Pain Symptom Manage. 2023;65:400–8, http://dx.doi.org/10.1016/j.jpainsymman.2022.12.146.

121. Cabezón-Gutiérrez L, Khosravi-Shahi P, Custodio-Cabello S, Muñiz-González F, Cano-Aguirre Mdel P, Alonso-Viteri S. Opioids for management of episodic breathlessness or dyspnea in patients with advanced disease. Support Care Cancer. 2016;24:4045–55, http://dx.doi.org/10.1007/s00520-016-3316-x.

122. Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care. J Pain Symptom Manage. 2013;45:885–91, http://dx.doi.org/10.1016/j.jpainsymman.2012.05.004.

123. Hui D, Bohlke K, Bao T, Campbell TC, Coyne PJ, Currow DC, et al. Management of dyspnea in advanced cancer: ASCO guideline. J Clin Oncol. 2021;39:1389–411, http://dx.doi.org/10.1200/JCO.20.03465.

124. Viola R, Kiteley C, Lloyd NS, Mackay JA, Wilson J, Wong RK. The management of dyspnea in cancer patients: a systematic review. Support Care Cancer. 2008;16:329–37, http://dx.doi.org/10.1007/s00520-007-0389-6.

125. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939–44, http://dx.doi.org/10.1136/thorax.57.11.939.

126. Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016;3:CD011008, http://dx.doi.org/10.1002/14651858.CD011008.pub2.

127. Hui D, Maddocks M, Johnson MJ, Ekström M, Simon ST, Ogliari AC, et al. Management of breathlessness in patients with cancer: ESMO clinical practice guidelines. ESMO Open. 2020;5:e001038, http://dx.doi.org/10.1136/esmoopen-2020-001038.

128. Luo N, Tan S, Li X, Singh S, Liu S, Chen C, et al. Efficacy and safety of opioids in treating cancer-related dyspnea: a systematic review and meta-analysis based on randomized controlled trials. J Pain Symptom Manage. 2021;61, http://dx.doi.org/10.1016/j.jpainsymman.2020.07.021, 198–210.e1.

129. Schmidt-Hansen M, Bennett MI, Arnold S, Bromham N, Hilgart JS, Page AJ, et al. Oxycodone for cancer-related pain. Cochrane Database Syst Rev. 2022;6:CD003870, http://dx.doi.org/10.1002/14651858.CD003870.pub7.

130. Taniguchi Y, Matsuda Y, Mori M, Ito M, Ikari T, Tokoro A, et al. Effectiveness and safety of opioids for dyspnea in patients with lung cancer: secondary analysis of multicenter prospective observational study. Transl Lung Cancer Res. 2022;11:2395–402, http://dx.doi.org/10.21037/tlcr-22-512.

131. Simon ST, Higginson IJ, Booth S, Harding R, Weingärtner V, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10:CD007354, http://dx.doi.org/10.1002/14651858.CD007354.pub3.

132. Yasuda S, Sugano K, Matsuda Y, Kako J, Takagi Y, Watanabe H, et al. Systematic review and meta-analysis of the efficacy of benzodiazepines for dyspnea in patients with cancer. Jpn J Clin Oncol. 2023;53:327–34, http://dx.doi.org/10.1093/jjco/hyac206.

133. Molassiotis A, Smith JA, Mazzone P, Blackhall F, Irwin RS. Symptomatic treatment of cough among adult patients with lung cancer: CHEST guideline and expert panel report. Chest. 2017;151:861–74, http://dx.doi.org/10.1016/j.chest.2016.12.028.

134. Molassiotis A, Bailey C, Caress A, Tan JY. Interventions for cough in cancer. Cochrane Database Syst Rev. 2015;5:CD007881, http://dx.doi.org/10.1002/14651858.CD007881.pub3.